Working… Menu

Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02833155
Recruitment Status : Completed
First Posted : July 14, 2016
Last Update Posted : May 7, 2019
Information provided by (Responsible Party):
EddingPharm Oncology Co., LTD.

Brief Summary:
The purpose of this study is to evaluate the safety and tolerance of entinostat administered orally as a single agent in a weekly dosing schedule. Additionally, this study will characterize the pharmacokinetics parameters in Chinese postmenopausal women with advanced breast cancer. And to define the profile of adverse events, including laboratory parameters in these subjects

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Entinostat Drug: Exemestane Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I and Pharmacokinetic Study to Evaluate Histone Deacetylase Inhibitor, Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer
Actual Study Start Date : August 29, 2016
Actual Primary Completion Date : July 18, 2018
Actual Study Completion Date : July 18, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Exemestane

Arm Intervention/treatment
Experimental: Entinostat and Exemestane

Patients receive entinostat PO on days 1, 8, 15, and 22. Entinostat in combination with exemestane will be repeatedly administered every 28 days in the absence of disease progression or unacceptable toxicity.

Exemestane wil be orally administered once daily for up to six months.

Drug: Entinostat
Given PO
Other Names:
  • MS-275
  • SDNX-275

Drug: Exemestane
Given PO

Primary Outcome Measures :
  1. Adverse events, 12-lead ECG, blood pressure/pulse, temperature, laboratory parameters and physical examination. [ Time Frame: Up to 28 days ]

Secondary Outcome Measures :
  1. Cmax,maximum plasma concentration [ Time Frame: Pre-dose, Days 1,2,3,4,5,7,15 and 22 ]
  2. tmax,time at which maximum plasma concentration was observed [ Time Frame: Pre-dose, Days 1,2,3,4,5,7,15 and 22 ]
  3. AUC 0-168h area under the plasma concentration-time curve from time zero to 168h [ Time Frame: Pre-dose, Days 1,2,3,4,5 and 7 ]
  4. AUC 0-inf,area under the plasma concentration-time curve from time zero to infinity [ Time Frame: Pre-dose, Days 1,2,3,4,5,7,15 and 22 ]
  5. T1/2, elimination half-life [ Time Frame: Pre-dose, Days 1,2,3,4,5,7,15 and 22 ]
  6. lambda z , apparent terminal phase elimination constant (λz) [ Time Frame: Pre-dose, Days 1,2,3,4,5,7,15 and 22 ]
  7. MRT,mean residence time [ Time Frame: Pre-dose, Days 1,2,3,4,5,7,15 and 22 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

For inclusion in the study patients should fulfil the following criteria:

  • Provision of informed consent prior to any study specific procedures.
  • Postmenopausal women aged ≤ 65years.
  • Estrogen receptor (ER) and / or progesterone receptor (PR) positive breast cancer confirmed by pathology.
  • Once received a non-steroidal aromatase inhibitor (letrozole / anastrozole) treatment, the disease recurrence or progression of breast cancer currently.
  • Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. And recently (past 2 months), weight loss is no more than 10% of average weight.
  • Patients must have a life expectancy >3 months.
  • Patients must have adequate organ and bone marrow function as defined by the following laboratory results.

    1. .absolute neutrophil count ( ANC )≥ 1,500 /mm3
    2. . Platelets≥100,000 /mm3
    3. . White blood cell count(WBC) ≥ 3,000 /mm3
    4. . Hemoglobin ≥ 9 g/dL.
    5. . Creatinine ≤ 1.5 times the upper limit of normal (ULN) for the institution or Creatinine clearance ≥ 60 ml/min/1.73m2
    6. . Total bilirubin ≤ 1.5 times the upper limit of normal for the institution(ULN)
    7. .Aspartate transaminases (AST/SGOT) or alanine transaminase (ALT/SGPT) ≤ 2.5 times the upper limit.
  • Patients must be able to take drugs and don't spit out, no malabsorption problem.
  • Able to comply with study procedures and follow-up examinations.

Exclusion Criteria:

  • Patients have known central nervous system metastasis except patients who have terminated steroid treatment for brain metastasis or spinal cord compression with remain disease stable for at least 1 month.
  • Previous treatment with entinostat or any other histone deacetylase inhibitor (Valproic acid, Chidamide etc).
  • Known allergy to any ingredients of entinostat and other drugs in the same class.
  • Women who are pregnant or breast-feeding (premenopausal). For women of childbearing potential, agreement to use a medically approved contraception measures (such as the intrauterine device (IUD), birth control pills or condoms) and to continue its use for the duration of study treatment and for 3 months after the last dose of study treatment.
  • Had received chemotherapy/radiotherapy or other anticancer therapy during the study or within 4 weeks of start of study treatment. Patients must completely recovered from all adverse events due to previous agents administered before 4 weeks (except alopecia).
  • Major surgery within 28 days of start of study treatment.
  • Patients have serious or uncontrolled systemic disease (such as severe liver dysfunction, severe renal dysfunction, poorly controlled diabetes, poorly controlled acute infections). Unstable or decompensated respiratory or cardiovascular disease, or peripheral vascular disease (including diabetic vascular disease), or organ transplantation.
  • Received potent CYP1A2 or CYP3A4 inducer and/or inhibitor (including but not limited following drug: ketoconazole, rifampicin, atazanavir, Clarithromycin, indinavir, itraconazole, nelfinavir, saquinavir, telithromycin, voriconazole, grapefruit or grapefruit juice, rifabutin, phenytoin, Carbamazepine and phenobarbital).
  • Patients with another active cancer (excluding basal cell carcinoma or cervical intraepithelial neoplasia [cervical intraepithelial neoplasia (CIN)/cervical carcinoma in situ] or melanoma in-situ). Prior history of other cancer is allowed, as long as there is no active disease within the prior 5 years.
  • Active bleeding or new thrombotic diseases using of anticoagulant drugs, patients with bleeding tendency.
  • Meet with any of the following criteria about cardiac parameters:
  • the corrected QT interval (QTc) >470 msec under resting conditions.
  • myocardial infarction or arterial thrombosis events within 6 months, or experiencing severe or unstable angina, or New York Heart Association (NYHA) Class III or IV disease.
  • Resting ECG imply any clinically significant abnormal on rhythm, conduction and morphology, for example, left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec.
  • Any factors (such as, heart failure, hypokalemia, inherited long QT syndrome, acquired long QT syndrome or family history of unexplained sudden death in immediate family members under 40 years old) or known combined drug (such as, sotalol, cisapride, clozapine, amiodarone and erythromycin, etc.) to increase risk of prolongation of QTc interval or arrhythmic event.
  • History of or known human immunodeficiency virus (HIV) infection
  • Known drug or long-term alcoholics.
  • Patient is currently enrolled in (or completed within 30 days before study drug administration) another investigational drug study.
  • Involvement in the planning and conduct of the study.
  • Possible of lower inclusion criteria according to the researchers (such as weak, etc), or the other is not suitable for this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02833155

Layout table for location information
China, Beijing
Cancer Hospital Chinese Academy Medical Sciences
Beijing, Beijing, China, 100021
China, Hunan
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
China, Sichuan
West China Hospital
Chengdu, Sichuan, China, 610041
China, Tianjin
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin, China, 300000
Sponsors and Collaborators
EddingPharm Oncology Co., LTD.

Layout table for additonal information
Responsible Party: EddingPharm Oncology Co., LTD. Identifier: NCT02833155     History of Changes
Other Study ID Numbers: EOC103-001
First Posted: July 14, 2016    Key Record Dates
Last Update Posted: May 7, 2019
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by EddingPharm Oncology Co., LTD.:
breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Histone Deacetylase Inhibitors